<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03334903</url>
  </required_header>
  <id_info>
    <org_study_id>OpioidNeurontinTKR</org_study_id>
    <nct_id>NCT03334903</nct_id>
  </id_info>
  <brief_title>Gabapentin Regimens and Their Effects on Opioid Consumption</brief_title>
  <official_title>Gabapentin Regimens and Their Effects on Opioid Consumption</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the best strategy of administering gabapentin in&#xD;
      connection with our current approach to perioperative pain management. We aim to evaluate two&#xD;
      different adjunct gabapentin regimens given in the perioperative period, and to identify&#xD;
      which manages patient pain more effectively and safely. In this evaluation, we will identify&#xD;
      the quantity of patients' opioid consumption, the quality of their pain management, and the&#xD;
      frequency and severity of any side effects they might experience.&#xD;
&#xD;
      Patients who are undergoing total knee replacement (TKR) and choose to participate will be&#xD;
      randomly assigned to a treatment group using computer-generated randomization. Patients in&#xD;
      group 1 (the control group) will receive the standard of care as pertains to gabapentin. This&#xD;
      consists of a single 600 mg dose of gabapentin administered to the patient approximately one&#xD;
      to two hours before surgery, then a dose of 600 mg each morning during postoperative&#xD;
      admission. Patients in Group 2 will receive 600 mg preoperatively, plus an additional&#xD;
      postoperative gabapentin regimen: they will take 300 mg of gabapentin every 8 hours for 1&#xD;
      week, then a single nightly dose of 300 mg for another month.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine the best strategy of administering gabapentin in&#xD;
      connection with our current approach to perioperative pain management. We aim to evaluate two&#xD;
      different adjunct gabapentin regimens given in the perioperative period, and to identify&#xD;
      which manages patient pain more effectively and safely. In this evaluation, we will identify&#xD;
      the quantity of patients' opioid consumption, the quality of their pain management, and the&#xD;
      frequency and severity of any side effects they might experience. The target enrollment is&#xD;
      68.&#xD;
&#xD;
      Patients who are undergoing total knee replacement (TKR) at Brigham and Women's Hospital will&#xD;
      be informed about the study and asked whether they would like to participate. Upon agreement,&#xD;
      a patient will sign his/her consent and will be assigned to a treatment group. Patients in&#xD;
      group 1 (the control group) will receive the standard of care as pertains to gabapentin. This&#xD;
      consists of a single 600 mg dose of gabapentin administered to the patient approximately one&#xD;
      to two hours before surgery, then a dose of 600 mg each morning during postoperative&#xD;
      admission. Patients in Group 2 will receive 600 mg preoperatively, plus an additional&#xD;
      postoperative gabapentin regimen: they will take 300 mg of gabapentin every 8 hours for 1&#xD;
      week, then a single nightly dose of 300 mg for another month.&#xD;
&#xD;
      Every patient being discharged from the hospital will receive from the nursing staff verbal&#xD;
      and written instructions - the latter of which will be either printed or in electronic form -&#xD;
      about narcotic medications. The instructions will explain when to use such medications and&#xD;
      how to taper off their consumption. Following discharge, patients will take gabapentin as&#xD;
      directed by their discharge instructions, and in the process track their opioid consumption&#xD;
      on their own in their diaries. They will also document their pain, nausea and satisfaction&#xD;
      levels according to the visual analogue scale (VAS). At the first post-operative appointment,&#xD;
      patients' levels of opioid use will be verified and compared to the amount recorded in each&#xD;
      diary; the actual number of tablets consumed will be compared with the documented amounts and&#xD;
      with the prescriptions they received. Patients receiving a new prescription will also receive&#xD;
      a matching diary for the total length of opioid treatment, including further directions on&#xD;
      how to wean themselves off their medications. Outcome measures will be collected at both&#xD;
      post-operative visits, the first occurring 8-10 days after surgery and the second 2-3 months&#xD;
      following. Additional data including length of stay, postoperative complications including&#xD;
      infection and readmission, Emergency Department visits, and routinely collected postoperative&#xD;
      functional outcome measures (PROMs) will be recorded.&#xD;
&#xD;
      The Principal Investigator (PI) will review all drug consumption data and patient-reported&#xD;
      outcome measures with the research assistant (RA) on a monthly basis as it is collected. The&#xD;
      PI will participate in the collection of outcome data at the first and second postoperative&#xD;
      visits. Data which could indicate a potential complication, whether related to the study or&#xD;
      not - such as heightened risk of adverse outcomes or non-compliance with the tracking diary -&#xD;
      will be addressed by the PI immediately. The PI will determine if the study should be altered&#xD;
      in any way or stopped for safety reasons. Reasons for stoppage include a rate of adverse&#xD;
      events greater than 10% in either group. Adverse events of primary concern include:&#xD;
&#xD;
        -  Excessive sleepiness&#xD;
&#xD;
        -  Allergic reactions to the opioid medications or gabapentin&#xD;
&#xD;
      All adverse events are recorded in an adverse event log, which will be kept by the RA&#xD;
      throughout the study. The PI will review the data on a monthly basis, as well as whenever the&#xD;
      RA alerts the PI to any potential adverse event. These checks will help to ensure validity&#xD;
      and patient safety. Unanticipated problems will be reported to the PHRC in accordance with&#xD;
      PHRC guidelines.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 15, 2018</start_date>
  <completion_date type="Actual">April 24, 2019</completion_date>
  <primary_completion_date type="Actual">April 24, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two-arm parallel design.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Opioid Consumption</measure>
    <time_frame>2-3 months following surgery (total amount measured at second postoperative appointment; means assessed afterwards).</time_frame>
    <description>Mean opioid consumption, measured in mg of morphine equivalents.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Days Taking Opioids</measure>
    <time_frame>2-3 months following surgery (measured at second postoperative appointment).</time_frame>
    <description>Number of days until patients are finished consuming opioid medications after discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS Score 1: &quot;How Much Pain do You Feel in Your Operative Site When Resting?&quot;</measure>
    <time_frame>2-3 months after surgery (at 2nd postoperative appointment)</time_frame>
    <description>Surgical site pain. Scale 0-10, with 0 best and 10 worst</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS Score 2: &quot;How Much Pain do You Feel in Your Operative Site When Moving?&quot;</measure>
    <time_frame>2-3 months following surgery (measured at second postoperative appointment).</time_frame>
    <description>Surgical site pain. Scale 0-10, with 0 best and 10 worst.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS Score 3: &quot;How Well Are You Sleeping?&quot;</measure>
    <time_frame>2-3 months following surgery (measured at second postoperative appointment).</time_frame>
    <description>Sleep quality. Scale 0-10 with 0 worst and 10 best.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS Score 4: &quot;How Bad is Your Nausea?&quot;</measure>
    <time_frame>2-3 months following surgery (measured at second postoperative appointment).</time_frame>
    <description>Nausea. Scale 0-10, with 0 best and 10 worst.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS Score 5: &quot;How Satisfied Are You With Your Pain Management?&quot;</measure>
    <time_frame>2-3 months following surgery (measured at second postoperative appointment).</time_frame>
    <description>Satisfaction. Scale 0-10 with 0 worst and 10 best.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <condition>Knee Pain Chronic</condition>
  <condition>Opioid Use</condition>
  <condition>Opioid Dependence</condition>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care includes one dose of 600 mg gabapentin in the immediate preoperative period (1-2 hours before surgery), then a dose of 600 mg each morning during postoperative admission.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Postoperative Gabapentin Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single preoperative dose of 600 mg, as described above, plus an additional postoperative regimen. Patients will take 300 mg gabapentin every 8 hours for 1 week after discharge, then a single nightly dose of 300 mg gabapentin for another month.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>600 mg gabapentin before and after surgery. 300 mg gabapentin for approx. 5 weeks after surgery.</description>
    <arm_group_label>Postoperative Gabapentin Regimen</arm_group_label>
    <other_name>Neurontin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Receiving surgery for total knee replacement (TKR)&#xD;
&#xD;
          -  Opioid naïve&#xD;
&#xD;
          -  Agrees to use tracking diary to monitor opioid consumption&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Over 75 years of age on the date of surgery&#xD;
&#xD;
          -  If female, pregnant&#xD;
&#xD;
          -  Has received investigational articles &lt; 30 days prior to enrollment or is currently&#xD;
             receiving investigational products or devices&#xD;
&#xD;
          -  Chronic pain syndrome&#xD;
&#xD;
          -  Taking chronic narcotics and/or taking more than 10 mg of codeine per day, any amount&#xD;
             of Hydrocodone, over 200 mg of tramadol per day, or any other narcotics prescribed for&#xD;
             moderate or severe pain&#xD;
&#xD;
          -  Involved in pain clinics for chronic pain, or pain that is not related to the surgical&#xD;
             site&#xD;
&#xD;
          -  On long-term gabapentin regimen&#xD;
&#xD;
          -  Taking Lyrica or Gralise&#xD;
&#xD;
          -  Known history of depression or has been treated for depression with medication&#xD;
&#xD;
          -  Has entertained suicidal thoughts and behaviors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Fitz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Faulkner Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bannister K, Qu C, Navratilova E, Oyarzo J, Xie JY, King T, Dickenson AH, Porreca F. Multiple sites and actions of gabapentin-induced relief of ongoing experimental neuropathic pain. Pain. 2017 Dec;158(12):2386-2395. doi: 10.1097/j.pain.0000000000001040.</citation>
    <PMID>28832395</PMID>
  </reference>
  <reference>
    <citation>Ozgencil E, Yalcin S, Tuna H, Yorukoglu D, Kecik Y. Perioperative administration of gabapentin 1,200 mg day-1 and pregabalin 300 mg day-1 for pain following lumbar laminectomy and discectomy: a randomised, double-blinded, placebo-controlled study. Singapore Med J. 2011 Dec;52(12):883-9.</citation>
    <PMID>22159931</PMID>
  </reference>
  <reference>
    <citation>Rusy LM, Hainsworth KR, Nelson TJ, Czarnecki ML, Tassone JC, Thometz JG, Lyon RM, Berens RJ, Weisman SJ. Gabapentin use in pediatric spinal fusion patients: a randomized, double-blind, controlled trial. Anesth Analg. 2010 May 1;110(5):1393-8. doi: 10.1213/ANE.0b013e3181d41dc2.</citation>
    <PMID>20418301</PMID>
  </reference>
  <reference>
    <citation>Stock CJ, Carpenter L, Ying J, Greene T. Gabapentin versus chlordiazepoxide for outpatient alcohol detoxification treatment. Ann Pharmacother. 2013 Jul-Aug;47(7-8):961-9. doi: 10.1345/aph.1R751. Epub 2013 Jun 18.</citation>
    <PMID>23780805</PMID>
  </reference>
  <reference>
    <citation>Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med. 2014 Jan;174(1):70-7. doi: 10.1001/jamainternmed.2013.11950.</citation>
    <PMID>24190578</PMID>
  </reference>
  <reference>
    <citation>Leung JG, Hall-Flavin D, Nelson S, Schmidt KA, Schak KM. The role of gabapentin in the management of alcohol withdrawal and dependence. Ann Pharmacother. 2015 Aug;49(8):897-906. doi: 10.1177/1060028015585849. Epub 2015 May 12. Review.</citation>
    <PMID>25969570</PMID>
  </reference>
  <reference>
    <citation>Grant MC, Lee H, Page AJ, Hobson D, Wick E, Wu CL. The Effect of Preoperative Gabapentin on Postoperative Nausea and Vomiting: A Meta-Analysis. Anesth Analg. 2016 Apr;122(4):976-85. doi: 10.1213/ANE.0000000000001120.</citation>
    <PMID>26991615</PMID>
  </reference>
  <reference>
    <citation>Misra S, Parthasarathi G, Vilanilam GC. The effect of gabapentin premedication on postoperative nausea, vomiting, and pain in patients on preoperative dexamethasone undergoing craniotomy for intracranial tumors. J Neurosurg Anesthesiol. 2013 Oct;25(4):386-91. doi: 10.1097/ANA.0b013e31829327eb.</citation>
    <PMID>23603887</PMID>
  </reference>
  <reference>
    <citation>Montazeri K, Kashefi P, Honarmand A. Pre-emptive gabapentin significantly reduces postoperative pain and morphine demand following lower extremity orthopaedic surgery. Singapore Med J. 2007 Aug;48(8):748-51.</citation>
    <PMID>17657384</PMID>
  </reference>
  <reference>
    <citation>Rai AS, Khan JS, Dhaliwal J, Busse JW, Choi S, Devereaux PJ, Clarke H. Preoperative pregabalin or gabapentin for acute and chronic postoperative pain among patients undergoing breast cancer surgery: A systematic review and meta-analysis of randomized controlled trials. J Plast Reconstr Aesthet Surg. 2017 Oct;70(10):1317-1328. doi: 10.1016/j.bjps.2017.05.054. Epub 2017 Jun 9. Review.</citation>
    <PMID>28751024</PMID>
  </reference>
  <reference>
    <citation>Arumugam S, Lau CS, Chamberlain RS. Use of preoperative gabapentin significantly reduces postoperative opioid consumption: a meta-analysis. J Pain Res. 2016 Sep 12;9:631-40. doi: 10.2147/JPR.S112626. eCollection 2016.</citation>
    <PMID>27672340</PMID>
  </reference>
  <reference>
    <citation>Hassani V, Pazouki A, Nikoubakht N, Chaichian S, Sayarifard A, Shakib Khankandi A. The effect of gabapentin on reducing pain after laparoscopic gastric bypass surgery in patients with morbid obesity: a randomized clinical trial. Anesth Pain Med. 2015 Feb 1;5(1):e22372. doi: 10.5812/aapm.22372. eCollection 2015 Feb.</citation>
    <PMID>25789237</PMID>
  </reference>
  <reference>
    <citation>Mardani-Kivi M, Mobarakeh MK, Keyhani S, Motlagh KH, Ekhtiari KS. Is gabapentin effective on pain management after arthroscopic anterior cruciate ligament reconstruction? A triple blinded randomized controlled trial. Arch Bone Jt Surg. 2013 Sep;1(1):18-22. Epub 2013 Sep 15.</citation>
    <PMID>25207278</PMID>
  </reference>
  <reference>
    <citation>Chiu TW, Leung CC, Lau EY, Burd A. Analgesic effects of preoperative gabapentin after tongue reconstruction with the anterolateral thigh flap. Hong Kong Med J. 2012 Feb;18(1):30-4.</citation>
    <PMID>22302908</PMID>
  </reference>
  <reference>
    <citation>Moore A, Costello J, Wieczorek P, Shah V, Taddio A, Carvalho JC. Gabapentin improves postcesarean delivery pain management: a randomized, placebo-controlled trial. Anesth Analg. 2011 Jan;112(1):167-73. doi: 10.1213/ANE.0b013e3181fdf5ee. Epub 2010 Nov 16.</citation>
    <PMID>21081764</PMID>
  </reference>
  <reference>
    <citation>Menda F, Köner O, Sayın M, Ergenoğlu M, Küçükaksu S, Aykaç B. Effects of single-dose gabapentin on postoperative pain and morphine consumption after cardiac surgery. J Cardiothorac Vasc Anesth. 2010 Oct;24(5):808-13. doi: 10.1053/j.jvca.2009.10.023. Epub 2010 Jan 6.</citation>
    <PMID>20056448</PMID>
  </reference>
  <reference>
    <citation>Türe H, Sayin M, Karlikaya G, Bingol CA, Aykac B, Türe U. The analgesic effect of gabapentin as a prophylactic anticonvulsant drug on postcraniotomy pain: a prospective randomized study. Anesth Analg. 2009 Nov;109(5):1625-31. doi: 10.1213/ane.0b013e3181b0f18b. Epub 2009 Aug 27.</citation>
    <PMID>19713257</PMID>
  </reference>
  <reference>
    <citation>Clivatti J, Sakata RK, Issy AM. Review of the use of gabapentin in the control of postoperative pain. Rev Bras Anestesiol. 2009 Jan-Feb;59(1):87-98. Review. English, Portuguese.</citation>
    <PMID>19374220</PMID>
  </reference>
  <reference>
    <citation>Pandey CK, Navkar DV, Giri PJ, Raza M, Behari S, Singh RB, Singh U, Singh PK. Evaluation of the optimal preemptive dose of gabapentin for postoperative pain relief after lumbar diskectomy: a randomized, double-blind, placebo-controlled study. J Neurosurg Anesthesiol. 2005 Apr;17(2):65-8.</citation>
    <PMID>15840990</PMID>
  </reference>
  <reference>
    <citation>Dierking G, Duedahl TH, Rasmussen ML, Fomsgaard JS, Møiniche S, Rømsing J, Dahl JB. Effects of gabapentin on postoperative morphine consumption and pain after abdominal hysterectomy: a randomized, double-blind trial. Acta Anaesthesiol Scand. 2004 Mar;48(3):322-7.</citation>
    <PMID>14982565</PMID>
  </reference>
  <reference>
    <citation>Ho KY, Gan TJ, Habib AS. Gabapentin and postoperative pain--a systematic review of randomized controlled trials. Pain. 2006 Dec 15;126(1-3):91-101. Epub 2006 Jul 18. Review.</citation>
    <PMID>16846695</PMID>
  </reference>
  <reference>
    <citation>Ucak A, Onan B, Sen H, Selcuk I, Turan A, Yilmaz AT. The effects of gabapentin on acute and chronic postoperative pain after coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth. 2011 Oct;25(5):824-9. doi: 10.1053/j.jvca.2010.11.017. Epub 2011 Jan 12.</citation>
    <PMID>21232979</PMID>
  </reference>
  <reference>
    <citation>Clarke H, Pereira S, Kennedy D, Gilron I, Katz J, Gollish J, Kay J. Gabapentin decreases morphine consumption and improves functional recovery following total knee arthroplasty. Pain Res Manag. 2009 May-Jun;14(3):217-22.</citation>
    <PMID>19547761</PMID>
  </reference>
  <reference>
    <citation>Smith RV, Havens JR, Walsh SL. Gabapentin misuse, abuse and diversion: a systematic review. Addiction. 2016 Jul;111(7):1160-74. doi: 10.1111/add.13324. Epub 2016 Mar 18. Review.</citation>
    <PMID>27265421</PMID>
  </reference>
  <reference>
    <citation>Ménigaux C, Adam F, Guignard B, Sessler DI, Chauvin M. Preoperative gabapentin decreases anxiety and improves early functional recovery from knee surgery. Anesth Analg. 2005 May;100(5):1394-1399. doi: 10.1213/01.ANE.0000152010.74739.B8.</citation>
    <PMID>15845693</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 3, 2017</study_first_submitted>
  <study_first_submitted_qc>November 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2017</study_first_posted>
  <results_first_submitted>December 23, 2020</results_first_submitted>
  <results_first_submitted_qc>February 1, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 18, 2021</results_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Wolfgang Fitz, M.D.</investigator_full_name>
    <investigator_title>Associate Orthopedic Surgeon</investigator_title>
  </responsible_party>
  <keyword>Total Knee Arthroplasty</keyword>
  <keyword>Neurontin</keyword>
  <keyword>Gabapentin</keyword>
  <keyword>Opioid Tapering</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis, Knee</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT03334903/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard of Care</title>
          <description>Standard of care includes one dose of 600 mg gabapentin in the immediate preoperative period (1-2 hours before surgery), then a dose of 600 mg each morning during postoperative admission.</description>
        </group>
        <group group_id="P2">
          <title>Postoperative Gabapentin Regimen</title>
          <description>Single preoperative dose of 600 mg, as described above, plus an additional postoperative regimen. Patients will take 300 mg gabapentin every 8 hours for 1 week after discharge, then a single nightly dose of 300 mg gabapentin for another month.&#xD;
Gabapentin: 600 mg gabapentin before and after surgery. 300 mg gabapentin for approx. 5 weeks after surgery.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Use of medical marijuana - determined ineligible later in study</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Surgery postponed</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard of Care</title>
          <description>Standard of care includes one dose of 600 mg gabapentin in the immediate preoperative period (1-2 hours before surgery), then a dose of 600 mg each morning during postoperative admission.</description>
        </group>
        <group group_id="B2">
          <title>Postoperative Gabapentin Regimen</title>
          <description>Single preoperative dose of 600 mg, as described above, plus an additional postoperative regimen. Patients will take 300 mg gabapentin every 8 hours for 1 week after discharge, then a single nightly dose of 300 mg gabapentin for another month.&#xD;
Gabapentin: 600 mg gabapentin before and after surgery. 300 mg gabapentin for approx. 5 weeks after surgery.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="68"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>68 total patients completed study, after dropout of 9 total participants from overall number enrolled</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="35"/>
                    <count group_id="B2" value="33"/>
                    <count group_id="B3" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.6" spread="6.8"/>
                    <measurement group_id="B2" value="64.2" spread="6.7"/>
                    <measurement group_id="B3" value="64.4" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="35"/>
                    <count group_id="B2" value="33"/>
                    <count group_id="B3" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="35"/>
                    <count group_id="B2" value="33"/>
                    <count group_id="B3" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.3" spread="4.5"/>
                    <measurement group_id="B2" value="32.1" spread="5.3"/>
                    <measurement group_id="B3" value="31.2" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Opioid Consumption</title>
        <description>Mean opioid consumption, measured in mg of morphine equivalents.</description>
        <time_frame>2-3 months following surgery (total amount measured at second postoperative appointment; means assessed afterwards).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Standard of care includes one dose of 600 mg gabapentin in the immediate preoperative period (1-2 hours before surgery), then a dose of 600 mg each morning during postoperative admission.</description>
          </group>
          <group group_id="O2">
            <title>Postoperative Gabapentin Regimen</title>
            <description>Single preoperative dose of 600 mg, as described above, plus an additional postoperative regimen. Patients will take 300 mg gabapentin every 8 hours for 1 week after discharge, then a single nightly dose of 300 mg gabapentin for another month.&#xD;
Gabapentin: 600 mg gabapentin before and after surgery. 300 mg gabapentin for approx. 5 weeks after surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Opioid Consumption</title>
          <description>Mean opioid consumption, measured in mg of morphine equivalents.</description>
          <units>morphine equivalents</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="287.0" spread="227.99"/>
                    <measurement group_id="O2" value="281.1" spread="230.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days Taking Opioids</title>
        <description>Number of days until patients are finished consuming opioid medications after discharge.</description>
        <time_frame>2-3 months following surgery (measured at second postoperative appointment).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Standard of care includes one dose of 600 mg gabapentin in the immediate preoperative period (1-2 hours before surgery), then a dose of 600 mg each morning during postoperative admission.</description>
          </group>
          <group group_id="O2">
            <title>Postoperative Gabapentin Regimen</title>
            <description>Single preoperative dose of 600 mg, as described above, plus an additional postoperative regimen. Patients will take 300 mg gabapentin every 8 hours for 1 week after discharge, then a single nightly dose of 300 mg gabapentin for another month.&#xD;
Gabapentin: 600 mg gabapentin before and after surgery. 300 mg gabapentin for approx. 5 weeks after surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Days Taking Opioids</title>
          <description>Number of days until patients are finished consuming opioid medications after discharge.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" spread="10.69"/>
                    <measurement group_id="O2" value="18.7" spread="18.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VAS Score 1: &quot;How Much Pain do You Feel in Your Operative Site When Resting?&quot;</title>
        <description>Surgical site pain. Scale 0-10, with 0 best and 10 worst</description>
        <time_frame>2-3 months after surgery (at 2nd postoperative appointment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Standard of care includes one dose of 600 mg gabapentin in the immediate preoperative period (1-2 hours before surgery), then a dose of 600 mg each morning during postoperative admission.</description>
          </group>
          <group group_id="O2">
            <title>Postoperative Gabapentin Regimen</title>
            <description>Single preoperative dose of 600 mg, as described above, plus an additional postoperative regimen. Patients will take 300 mg gabapentin every 8 hours for 1 week after discharge, then a single nightly dose of 300 mg gabapentin for another month.&#xD;
Gabapentin: 600 mg gabapentin before and after surgery. 300 mg gabapentin for approx. 5 weeks after surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>VAS Score 1: &quot;How Much Pain do You Feel in Your Operative Site When Resting?&quot;</title>
          <description>Surgical site pain. Scale 0-10, with 0 best and 10 worst</description>
          <units>score on 10-point scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.26" spread="1.36"/>
                    <measurement group_id="O2" value="2.46" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VAS Score 2: &quot;How Much Pain do You Feel in Your Operative Site When Moving?&quot;</title>
        <description>Surgical site pain. Scale 0-10, with 0 best and 10 worst.</description>
        <time_frame>2-3 months following surgery (measured at second postoperative appointment).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Standard of care includes one dose of 600 mg gabapentin in the immediate preoperative period (1-2 hours before surgery), then a dose of 600 mg each morning during postoperative admission.</description>
          </group>
          <group group_id="O2">
            <title>Postoperative Gabapentin Regimen</title>
            <description>Single preoperative dose of 600 mg, as described above, plus an additional postoperative regimen. Patients will take 300 mg gabapentin every 8 hours for 1 week after discharge, then a single nightly dose of 300 mg gabapentin for another month.&#xD;
Gabapentin: 600 mg gabapentin before and after surgery. 300 mg gabapentin for approx. 5 weeks after surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>VAS Score 2: &quot;How Much Pain do You Feel in Your Operative Site When Moving?&quot;</title>
          <description>Surgical site pain. Scale 0-10, with 0 best and 10 worst.</description>
          <units>score on a 10-point scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.84" spread="1.54"/>
                    <measurement group_id="O2" value="3.54" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VAS Score 3: &quot;How Well Are You Sleeping?&quot;</title>
        <description>Sleep quality. Scale 0-10 with 0 worst and 10 best.</description>
        <time_frame>2-3 months following surgery (measured at second postoperative appointment).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Standard of care includes one dose of 600 mg gabapentin in the immediate preoperative period (1-2 hours before surgery), then a dose of 600 mg each morning during postoperative admission.</description>
          </group>
          <group group_id="O2">
            <title>Postoperative Gabapentin Regimen</title>
            <description>Single preoperative dose of 600 mg, as described above, plus an additional postoperative regimen. Patients will take 300 mg gabapentin every 8 hours for 1 week after discharge, then a single nightly dose of 300 mg gabapentin for another month.&#xD;
Gabapentin: 600 mg gabapentin before and after surgery. 300 mg gabapentin for approx. 5 weeks after surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>VAS Score 3: &quot;How Well Are You Sleeping?&quot;</title>
          <description>Sleep quality. Scale 0-10 with 0 worst and 10 best.</description>
          <units>score on a 10-point scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.73" spread="2.16"/>
                    <measurement group_id="O2" value="6.38" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VAS Score 4: &quot;How Bad is Your Nausea?&quot;</title>
        <description>Nausea. Scale 0-10, with 0 best and 10 worst.</description>
        <time_frame>2-3 months following surgery (measured at second postoperative appointment).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Standard of care includes one dose of 600 mg gabapentin in the immediate preoperative period (1-2 hours before surgery), then a dose of 600 mg each morning during postoperative admission.</description>
          </group>
          <group group_id="O2">
            <title>Postoperative Gabapentin Regimen</title>
            <description>Single preoperative dose of 600 mg, as described above, plus an additional postoperative regimen. Patients will take 300 mg gabapentin every 8 hours for 1 week after discharge, then a single nightly dose of 300 mg gabapentin for another month.&#xD;
Gabapentin: 600 mg gabapentin before and after surgery. 300 mg gabapentin for approx. 5 weeks after surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>VAS Score 4: &quot;How Bad is Your Nausea?&quot;</title>
          <description>Nausea. Scale 0-10, with 0 best and 10 worst.</description>
          <units>score on a 10-point scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="0.53"/>
                    <measurement group_id="O2" value="0.17" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VAS Score 5: &quot;How Satisfied Are You With Your Pain Management?&quot;</title>
        <description>Satisfaction. Scale 0-10 with 0 worst and 10 best.</description>
        <time_frame>2-3 months following surgery (measured at second postoperative appointment).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Standard of care includes one dose of 600 mg gabapentin in the immediate preoperative period (1-2 hours before surgery), then a dose of 600 mg each morning during postoperative admission.</description>
          </group>
          <group group_id="O2">
            <title>Postoperative Gabapentin Regimen</title>
            <description>Single preoperative dose of 600 mg, as described above, plus an additional postoperative regimen. Patients will take 300 mg gabapentin every 8 hours for 1 week after discharge, then a single nightly dose of 300 mg gabapentin for another month.&#xD;
Gabapentin: 600 mg gabapentin before and after surgery. 300 mg gabapentin for approx. 5 weeks after surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>VAS Score 5: &quot;How Satisfied Are You With Your Pain Management?&quot;</title>
          <description>Satisfaction. Scale 0-10 with 0 worst and 10 best.</description>
          <units>score on a 10-point scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.83" spread="2.23"/>
                    <measurement group_id="O2" value="8.48" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events collected through study completion, an average of 3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Standard of Care</title>
          <description>Standard of care includes one dose of 600 mg gabapentin in the immediate preoperative period (1-2 hours before surgery), then a dose of 600 mg each morning during postoperative admission.</description>
        </group>
        <group group_id="E2">
          <title>Postoperative Gabapentin Regimen</title>
          <description>Single preoperative dose of 600 mg, as described above, plus an additional postoperative regimen. Patients will take 300 mg gabapentin every 8 hours for 1 week after discharge, then a single nightly dose of 300 mg gabapentin for another month.&#xD;
Gabapentin: 600 mg gabapentin before and after surgery. 300 mg gabapentin for approx. 5 weeks after surgery.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI Distress</sub_title>
                <description>GI distress from anesthesia / narcotics post-operative</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Wolfgang Fitz</name_or_title>
      <organization>Brigham and Women's Hospital</organization>
      <phone>6177325500</phone>
      <email>wfitz@bwh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

